JP2018521034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521034A5 JP2018521034A5 JP2017565726A JP2017565726A JP2018521034A5 JP 2018521034 A5 JP2018521034 A5 JP 2018521034A5 JP 2017565726 A JP2017565726 A JP 2017565726A JP 2017565726 A JP2017565726 A JP 2017565726A JP 2018521034 A5 JP2018521034 A5 JP 2018521034A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- alkyl
- independently
- aryl
- membered heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 70
- 125000001931 aliphatic group Chemical group 0.000 claims description 51
- 208000015114 central nervous system disease Diseases 0.000 claims description 48
- 125000000623 heterocyclic group Chemical group 0.000 claims description 47
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 44
- 208000010877 cognitive disease Diseases 0.000 claims description 32
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 31
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000012453 solvate Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 16
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 206010012289 Dementia Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 6
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 5
- 230000005494 condensation Effects 0.000 claims description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 5
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000036626 Mental retardation Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000000561 anti-psychotic effect Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 229960004640 memantine Drugs 0.000 claims description 4
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229960004372 aripiprazole Drugs 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- 229960003980 galantamine Drugs 0.000 claims description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 2
- 229960005017 olanzapine Drugs 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 229960000607 ziprasidone Drugs 0.000 claims description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021105189A JP2021152071A (ja) | 2015-06-19 | 2021-06-24 | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182336P | 2015-06-19 | 2015-06-19 | |
| US62/182,336 | 2015-06-19 | ||
| PCT/US2016/038224 WO2016205739A1 (en) | 2015-06-19 | 2016-06-17 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021105189A Division JP2021152071A (ja) | 2015-06-19 | 2021-06-24 | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521034A JP2018521034A (ja) | 2018-08-02 |
| JP2018521034A5 true JP2018521034A5 (cg-RX-API-DMAC7.html) | 2019-06-13 |
| JP6987384B2 JP6987384B2 (ja) | 2021-12-22 |
Family
ID=57546444
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565726A Active JP6987384B2 (ja) | 2015-06-19 | 2016-06-17 | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
| JP2021105189A Withdrawn JP2021152071A (ja) | 2015-06-19 | 2021-06-24 | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021105189A Withdrawn JP2021152071A (ja) | 2015-06-19 | 2021-06-24 | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10815242B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3310785B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6987384B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113264939A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016279052A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2990004C (cg-RX-API-DMAC7.html) |
| EA (1) | EA036844B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL256354B (cg-RX-API-DMAC7.html) |
| MA (1) | MA42624A (cg-RX-API-DMAC7.html) |
| MX (2) | MX392119B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016205739A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201800360B (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4032889A1 (en) | 2013-12-20 | 2022-07-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CA2990004C (en) | 2015-06-19 | 2024-04-23 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio, Inc. | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2019288382B2 (en) * | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2020165802A1 (en) * | 2019-02-13 | 2020-08-20 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors |
| MX2022007725A (es) * | 2019-12-19 | 2022-07-19 | Agenebio Inc | Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. |
| IL299761A (en) * | 2020-07-10 | 2023-03-01 | Agenebio Inc | GABAA alpha 5 agonist polymorphs and methods of use for the treatment of cognitive impairment |
| AU2023324882A1 (en) | 2022-08-19 | 2025-03-20 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2024196801A1 (en) * | 2023-03-17 | 2024-09-26 | LAPKO INC, dba AFECTA PHARMACEUTICALS | Methods for treating aberrant behavior and motor activity |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| NL7305644A (cg-RX-API-DMAC7.html) | 1972-04-20 | 1973-10-23 | ||
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| EP0402644B1 (en) | 1989-05-19 | 1995-08-16 | Hoechst-Roussel Pharmaceuticals Incorporated | N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| ATE180475T1 (de) | 1990-09-21 | 1999-06-15 | Rohm & Haas | Dihydropyridazinone und pyridazinone als fungizide |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5500438A (en) | 1991-05-24 | 1996-03-19 | E. I. Du Pont De Nemours And Company | Arthropodicidal anilides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (cg-RX-API-DMAC7.html) * | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| CA2182981C (en) | 1994-03-02 | 2006-10-17 | Leonardus Petrus Carla Delbressine | Sublingual or buccal pharmaceutical composition |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| AU1041599A (en) | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| EP1129094A2 (en) | 1998-11-12 | 2001-09-05 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| EP1157989B1 (en) | 1999-03-03 | 2004-09-22 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) * | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| CZ20032338A3 (cs) | 2001-03-01 | 2004-08-18 | Pfizeráproductsáinc | Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| US20050071088A1 (en) | 2001-08-13 | 2005-03-31 | Landfield Philip W | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| JP2005518411A (ja) | 2002-01-16 | 2005-06-23 | エンド ファーマシューティカルズ インコーポレーテッド | 中枢神経系の障害を治療する製薬組成物及び方法 |
| CA2495285A1 (en) | 2002-08-13 | 2004-02-19 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for gaba receptors |
| GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| WO2004037234A2 (en) | 2002-10-24 | 2004-05-06 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| US20040191803A1 (en) | 2002-11-22 | 2004-09-30 | Michela Gallagher | Target for therapy of cognitive impairment |
| TW200526194A (en) | 2003-10-22 | 2005-08-16 | Merz Pharma Gmbh & Co Kgaa | The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic Aβ peptides in amyloidopathies |
| CN101374525A (zh) | 2004-09-23 | 2009-02-25 | 莫茨药物股份两合公司 | 美金刚治疗儿童行为障碍 |
| AU2005293820B2 (en) | 2004-10-12 | 2010-11-25 | F. Hoffmann-La Roche Ag | Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders |
| RU2007114763A (ru) | 2004-10-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Галогенозамещенные производные бензодиазепинов |
| CA2584259C (en) * | 2004-10-20 | 2013-04-02 | F. Hoffmann-La Roche Ag | Imidazo-benzodiazepine derivatives |
| EP1828194B1 (en) | 2004-12-14 | 2008-05-28 | F. Hoffmann-Roche AG | Tetracyclic imidazo-benzodiazepines as gaba receptors modulators |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| CA2607226A1 (en) | 2005-05-16 | 2007-02-15 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| BRPI0617204A2 (pt) | 2005-10-11 | 2011-07-19 | Hoffmann La Roche | derivados de imidazo benzodiazepina |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| EP2330891A1 (en) | 2008-09-24 | 2011-06-15 | E. I. du Pont de Nemours and Company | Fungicidal pyridazines |
| CA2737452C (en) | 2008-09-25 | 2018-05-22 | Vive Nano Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
| WO2010120370A2 (en) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as gabab receptor ligands |
| WO2011085406A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| PH12013500676A1 (en) * | 2010-11-05 | 2013-05-06 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| CA2818025A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| US20130237530A1 (en) | 2010-11-15 | 2013-09-12 | Agenebio, Inc. | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment |
| WO2012161133A1 (ja) | 2011-05-20 | 2012-11-29 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| US20150224094A1 (en) | 2012-09-10 | 2015-08-13 | Ophirex, Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| EP4032889A1 (en) * | 2013-12-20 | 2022-07-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CA2990004C (en) | 2015-06-19 | 2024-04-23 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio, Inc. | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| CN108567787A (zh) | 2017-03-10 | 2018-09-25 | 辛衍雪 | 一种治疗慢性阻塞性肺病的药物组合物 |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2016
- 2016-06-17 CA CA2990004A patent/CA2990004C/en active Active
- 2016-06-17 EA EA201890090A patent/EA036844B1/ru not_active IP Right Cessation
- 2016-06-17 WO PCT/US2016/038224 patent/WO2016205739A1/en not_active Ceased
- 2016-06-17 CN CN202110582826.3A patent/CN113264939A/zh active Pending
- 2016-06-17 IL IL256354A patent/IL256354B/en unknown
- 2016-06-17 MA MA042624A patent/MA42624A/fr unknown
- 2016-06-17 MX MX2020013374A patent/MX392119B/es unknown
- 2016-06-17 MX MX2017015752A patent/MX384734B/es unknown
- 2016-06-17 AU AU2016279052A patent/AU2016279052A1/en not_active Abandoned
- 2016-06-17 CN CN201680042224.6A patent/CN108026107B/zh active Active
- 2016-06-17 US US15/736,697 patent/US10815242B2/en active Active
- 2016-06-17 JP JP2017565726A patent/JP6987384B2/ja active Active
- 2016-06-17 EP EP16812577.1A patent/EP3310785B1/en active Active
-
2018
- 2018-01-18 ZA ZA2018/00360A patent/ZA201800360B/en unknown
-
2020
- 2020-09-22 US US17/028,917 patent/US11312721B2/en active Active
-
2021
- 2021-01-13 AU AU2021200164A patent/AU2021200164B2/en active Active
- 2021-06-24 JP JP2021105189A patent/JP2021152071A/ja not_active Withdrawn
-
2022
- 2022-02-04 US US17/592,679 patent/US12024525B2/en active Active